1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Sanofi/Regeneron's Great ODYSSEY ESCAPE – How Big Is Praluent's Apheresis Benefit?

 
• By Alexandra Shimmings

The full data for Sanofi/Regeneron's ODYSSEY ESCAPE study of their PCSK9 inhibitor Praluent confirm its use in reducing the need for expensive apheresis procedures in severe hypercholesterolemia patients, but the extent of the cost savings is still unclear.

Restricted by cholesterol as a confined person behind prison bars made of clogged artery and atherosclerosis disease arteries as a medical concept with blood cells that is blocked by plaque buildup.
• Source: Shutterstock

Sanofi and Regeneron Pharmaceuticals Inc. have strengthened the case for using their PCSK9 inhibitor Praluent (alirocumab) to reduce or even eliminate the need for expensive and cumbersome apheresis procedures in patients with heterozygous familial hypercholesterolemia (HeFH) with the presentation of the full results of their ODYSSEY ESCAPE study during a Hotline session at the European Society of Cardiology meeting in Rome this weekend. The data have simultaneously been published in the European Heart Journal.

Both the marketed PCSK9 inhibitors, Praluent and Amgen Inc.'s Repatha (evolocumab), have struggled to gain sales traction in the year since their arrival, hampered by negative sentiment over their high prices. The new data should help Sanofi and Regeneron in their attempts to convince payers that the drug is worth the money for severe patients at least

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Merck & Co. CMO Eliav Barr Assures On Pipeline As Keytruda LOE Looms Large

 
• By Jessica Merrill

Chief medical officer Eliav Barr, responsible for overseeing clinical development, talked to Scrip in an interview at Merck’s headquarters about the company’s pipeline diversification.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.